ArticleDiabetologia2006
Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes.
Article in Diabetologia, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- Trial
- Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.Diabetes technology & therapeutics · 2013Trial
- Antiglycation approach in selected autoimmune diseases: Where do we stand?Redox biology · 2026Review
- Impact of controlled type 2 diabetes on muscle-tendon mechanics.Acta diabetologica · 2026Article
- Plasma AGE and Oxidation Products, Renal Function, and Preeclampsia in Pregnant Women with Type 1 Diabetes: A Prospective Observational Study.Journal of diabetes research · 2023Observational
- Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?Nutrients · 2022Review
- Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC.BMJ open diabetes research & care · 2022Article
- Advanced Glycation End Products in the Skin: Molecular Mechanisms, Methods of Measurement, and Inhibitory Pathways.Frontiers in medicine · 2022Review
- The structural role of osteocalcin in bone biomechanics and its alteration in Type-2 Diabetes.Scientific reports · 2020Article
- Pathways of the Maillard reaction under physiological conditions.Glycoconjugate journal · 2016Review
- Reduced Venous Compliance in Young Women with Type 1 Diabetes - Further Aggravated by Prolonged Elevated Levels of HbA1c.Frontiers in endocrinology · 2016Article
- Decreased circulatory response to hypovolemic stress in young women with type 1 diabetes.Diabetes care · 2013Article
- The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study.Diabetes care · 2013Article
- Haptoglobin genotype and its role in diabetic cardiovascular disease.Journal of cardiovascular translational research · 2012Review
- Advanced glycation end products: Key players in skin aging?Dermato-endocrinology · 2012Article
- Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.Translational research : the journal of laboratory and clinical medicine · 2012Review
- Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers.Translational research : the journal of laboratory and clinical medicine · 2012Review
- Protection from diabetes-induced peripheral sensory neuropathy--a role for elevated glyoxalase I?Experimental neurology · 2012Article
- EnRAGEd about death in type 1 diabetes.Diabetologia · 2011Article
- Characterisation of glyoxalase I in a streptozocin-induced mouse model of diabetes with painful and insensate neuropathy.Diabetologia · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
aims/hypothesisWe determined whether oxidative damage in collagen is increased in (1) patients with diabetes; (2) patients with diabetic complications; and (3) subjects from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study, with comparison of subjects from the former standard vs intensive treatment groups 4 years after DCCT completion. SUBJECTS, MATERIALS AND
methodsWe quantified the early glycation product fructose-lysine, the two AGEs N (epsilon)-(carboxymethyl)lysine (CML) and pentosidine, and the oxidised amino acid methionine sulphoxide (MetSO) in skin collagen from 96 patients with type 1 diabetes (taken from three groups: DCCT/EDIC patients and clinic patients from South Carolina and Scotland) and from 78 healthy subjects.
resultsFructose-lysine was increased in diabetic patients (p<0.0001), both with or without complications (p<0.0001). Controlling for HbA(1c), rates of accumulation of AGEs were higher in diabetic patients than control subjects, regardless of whether the former had complications (CML and pentosidine given as log(e)[pentosidine]) or not (CML only) (all p<0.0001). MetSO (log(e)[MetSO]) also accumulated more rapidly in diabetic patients with complications than in controls (p<0.0001), but rates were similar in patients without complications and controls. For all three products, rates of accumulation with age were significantly higher in diabetic patients with complications than in those without (all p<0.0001). At 4 years after the end of the DCCT, no differences were found between the previous DCCT management groups for fructose-lysine, AGEs or MetSO. CONCLUSIONS/
interpretationThe findings suggest that in type 1 diabetic patients enhanced oxidative damage to collagen is associated with the presence of vascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.